MedPath

ORION BIOTECHNOLOGY POLSKA SP Z O O

🇵🇱Poland
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Early Phase 1:1
Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (50.0%)
Phase 1
1 (50.0%)

Study of OB-002 in Patients With Refractory Metastatic Cancer

Phase 1
Withdrawn
Conditions
Metastatic Cancer
Metastatic Urothelial Carcinoma
Metastatic Colorectal Cancer
Metastatic Pancreatic Cancer
Metastatic Gastric Cancer
Metastatic Breast Cancer
Interventions
First Posted Date
2023-07-11
Last Posted Date
2025-04-09
Lead Sponsor
Orion Biotechnology Polska Sp. z o.o.
Target Recruit Count
36
Registration Number
NCT05940844

OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults

Early Phase 1
Completed
Conditions
HIV Prevention
Interventions
Drug: Placebo
First Posted Date
2021-03-10
Last Posted Date
2021-03-18
Lead Sponsor
Orion Biotechnology Polska Sp. z o.o.
Target Recruit Count
60
Registration Number
NCT04791007
Locations
🇵🇱

BioVirtus Centrum Medyczne Sp. z o.o., Józefów, Poland

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.